Lipocine Inc. (LPCN)Healthcare | Biotechnology | Salt Lake City, United States | NasdaqCM
2.17 USD
-0.06
(-2.691%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.13 -0.04 (-0.040%) ⇩ (Aug. 28, 2026, 4:48 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:25 a.m. EDT
The investment case for this biotech stock has collapsed due to a catastrophic multi-year decline and deteriorating fundamentals. The price has lost 95% of its value over the last nine years, with six consecutive years of negative annual returns, signaling a deep structural failure rather than a temporary setback. This trajectory is compounded by shrinking revenues, which fell nearly 70% year-over-year, alongside severe losses in profitability with negative operating margins and equity returns. The balance sheet, while currently showing low debt relative to cash, cannot mask the reality that the core business is failing to generate value or grow. Recent news confirms this distress, citing a failed Phase 3 trial that triggered a massive stock drop and forced a strategic reevaluation. With no dividend history to provide income and a forward P/E indicating negative earnings, there is no margin of safety here; the market has already priced in the business model's inability to sustain itself. The recent price action shows a flat, depressed range near the lows, offering no immediate technical relief. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.056703 |
| AutoARIMA | 0.056703 |
| MSTL | 0.060719 |
| AutoTheta | 0.356130 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.378 |
| Excess Kurtosis | -1.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.184 |
| Revenue per Share | 0.24 |
| Market Cap | 17,890,030 |
| Forward P/E | -1.75 |
| Beta | 0.46 |
| Website | https://www.lipocine.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.23103446 |
| Address1 | 675 Arapeen Drive |
| Address2 | Suite 202 |
| All Time High | 326.91 |
| All Time Low | 1.81 |
| Ask | 2.76 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 35,510 |
| Average Daily Volume3 Month | 62,875 |
| Average Volume | 62,875 |
| Average Volume10Days | 35,510 |
| Beta | 0.46 |
| Bid | 1.6 |
| Bid Size | 2 |
| Book Value | 2.64 |
| City | Salt Lake City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.17 |
| Current Ratio | 11.478 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.215 |
| Day Low | 2.13 |
| Debt To Equity | 1.184 |
| Display Name | Lipocine |
| Earnings Timestamp End | 1,755,174,600 |
| Earnings Timestamp Start | 1,755,174,600 |
| Ebitda | -12,509,986 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.409 |
| Enterprise To Revenue | -3.261 |
| Enterprise Value | -5,118,773 |
| Eps Forward | -1.24 |
| Eps Trailing Twelve Months | -1.85 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 801 994 7388 |
| Fifty Day Average | 2.2384 |
| Fifty Day Average Change | -0.068399906 |
| Fifty Day Average Change Percent | -0.0305575 |
| Fifty Two Week Change Percent | -23.103445 |
| Fifty Two Week High | 12.37 |
| Fifty Two Week High Change | -10.2 |
| Fifty Two Week High Change Percent | -0.8245756 |
| Fifty Two Week Low | 1.81 |
| Fifty Two Week Low Change | 0.36000013 |
| Fifty Two Week Low Change Percent | 0.19889511 |
| Fifty Two Week Range | 1.81 - 12.37 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,382,448,600,000 |
| Float Shares | 6,552,450 |
| Forward Eps | -1.24 |
| Forward P E | -1.75 |
| Free Cashflow | -6,939,857 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Fullday Change | -0.0599999 |
| Fullday Change Percent | -2.69058 |
| Fullday Price | 2.13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,569,460 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04507 |
| Held Percent Institutions | 0.36188 |
| Implied Shares Outstanding | 8,244,253 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,683,849,600 |
| Last Split Factor | 1:17 |
| Long Business Summary | Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah. |
| Long Name | Lipocine Inc. |
| Market | us_market |
| Market Cap | 17,890,030 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_8057882 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -11,851,405 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 18,384,684 |
| Number Of Analyst Opinions | 1 |
| Open | 2.2039 |
| Operating Cashflow | -11,190,794 |
| Operating Margins | -14.9514 |
| Payout Ratio | 0.0 |
| Phone | 801 994 7383 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -1.8433162 |
| Post Market Price | 2.13 |
| Post Market Time | 1,787,950,109 |
| Previous Close | 2.23 |
| Price Hint | 4 |
| Price To Book | 0.8219697 |
| Price To Sales Trailing12 Months | 11.398844 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.392 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -2.69058 |
| Regular Market Day High | 2.215 |
| Regular Market Day Low | 2.13 |
| Regular Market Day Range | 2.13 - 2.215 |
| Regular Market Open | 2.2039 |
| Regular Market Previous Close | 2.23 |
| Regular Market Price | 2.17 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 19,546 |
| Return On Assets | -0.37043 |
| Return On Equity | -0.60939 |
| Revenue Growth | -0.695 |
| Revenue Per Share | 0.24 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 8,244,253 |
| Shares Percent Shares Out | 0.0115 |
| Shares Short | 94,427 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 123,024 |
| Short Name | Lipocine Inc. |
| Short Percent Of Float | 0.0117 |
| Short Ratio | 2.42 |
| Source Interval | 15 |
| State | UT |
| Symbol | LPCN |
| Target High Price | 6.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 6.0 |
| Total Cash | 23,266,608 |
| Total Cash Per Share | 2.822 |
| Total Debt | 257,807 |
| Total Revenue | 1,569,460 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.52125 |
| Two Hundred Day Average Change | -2.3512497 |
| Two Hundred Day Average Change Percent | -0.5200442 |
| Type Disp | Equity |
| Volume | 19,546 |
| Website | https://www.lipocine.com |
| Zip | 84,108 |